首页> 中文期刊>临床与实验病理学杂志 >肝癌细胞中PKC zeta的表达及临床意义

肝癌细胞中PKC zeta的表达及临床意义

     

摘要

Purpose To observe the expression of PKC zeta on Bel-7402 cells and the role in the cell chemotaxis, in order to provide an experimental basis in clinical treatment and prognosis evaluation. Methods The expression of PKC zeta in Bel-7402 cells was analyzed by immunocytochemistry. MTT assay was used to observe the inhibitory effects of PKC zeta inhihitor on Bel-7402 cells at various concentrations and different time points. Wound healing assay was used to observe migration distances of the cells in different periods.Chemotaxis assays were done to test the chemotaxis effect of PKC zeta inhibitor. Adhesion assay was carried out to detect the adhesion ability. Results Immunohistochemical results showed that PKC zeta protein was positive expression in cytoplasm; The distances were reduced in wound healing assay and the numher of cells decreased in adhesion and chemotaxis assays after being treated by PKC zeta inhibitor ( P < 0. 05 ). Conclusions PKC zeta protein is positively expressed in Bel-7402 cells. By inhibiting the expression of PKC zeta, the cancer cell invasion and metastasis can be reduced.%目的 观察PKC zeta在肝癌细胞株Bel-7402细胞中的表达及其在趋化运动中的作用,为PKC zeta在临床肝癌的治疗和预后评价中的应用提供实验依据.方法 免疫组化染色,检测PKC zeta在肝癌细胞株Bel-7402细胞中的表达情况;四甲基偶氮唑蓝(MTT)检测,观察经PKC zeta抑制剂处理后肝癌细胞株Bel-7402不同时间和不同药物浓度的生长增殖情况;划痕实验观察PKC zeta抑制剂处理前后细胞在不同时间段的迁移距离;黏附实验观察PKC zeta抑制剂处理前后肝癌细胞Bel-7402在盖玻片上黏附细胞的数量差别;趋化实验观察PKC zeta抑制剂处理前后肝癌细胞Bel-7402在趋化因子影响下穿过8 μm微孔滤膜细胞数的差异.结果 PKC zeta蛋白在肝癌Bel-7402细胞胞质中呈阳性表达;经药物处理的细胞一定时间内,迁移距离缩小,黏附细胞数量减少,趋化穿膜的细胞数也减少,差异具有显著性(P<0.05).结论 PKC zeta在肝癌细胞株Bel-7402中阳性表达,且若抑制PKC zeta的表达能降低细胞侵袭转移能力.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号